Bridgewater Associates LP Has $3.88 Million Holdings in Hologic, Inc. (NASDAQ:HOLX)

Bridgewater Associates LP trimmed its position in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 67.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 53,797 shares of the medical equipment provider's stock after selling 111,030 shares during the period. Bridgewater Associates LP's holdings in Hologic were worth $3,878,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Brooklyn Investment Group raised its position in shares of Hologic by 14.7% during the 4th quarter. Brooklyn Investment Group now owns 1,131 shares of the medical equipment provider's stock valued at $82,000 after acquiring an additional 145 shares during the last quarter. Smartleaf Asset Management LLC increased its position in shares of Hologic by 36.9% in the 4th quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider's stock valued at $43,000 after buying an additional 159 shares in the last quarter. Trivant Custom Portfolio Group LLC grew its holdings in shares of Hologic by 2.1% during the fourth quarter. Trivant Custom Portfolio Group LLC now owns 8,348 shares of the medical equipment provider's stock worth $602,000 after buying an additional 169 shares in the last quarter. UMB Bank n.a. lifted its stake in Hologic by 4.1% in the 4th quarter. UMB Bank n.a. now owns 4,758 shares of the medical equipment provider's stock valued at $343,000 after acquiring an additional 188 shares in the last quarter. Finally, Capital Investment Counsel Inc lifted its stake in Hologic by 3.6% in the 4th quarter. Capital Investment Counsel Inc now owns 5,724 shares of the medical equipment provider's stock valued at $413,000 after acquiring an additional 200 shares in the last quarter. 94.73% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of brokerages have recently issued reports on HOLX. Royal Bank of Canada dropped their price objective on Hologic from $88.00 to $85.00 and set a "sector perform" rating on the stock in a research note on Thursday, February 6th. Leerink Partnrs cut Hologic from a "strong-buy" rating to a "hold" rating in a research note on Thursday, February 6th. Morgan Stanley decreased their price objective on Hologic from $84.00 to $82.00 and set an "equal weight" rating on the stock in a report on Monday, January 13th. Citigroup decreased their price objective on Hologic from $80.00 to $70.00 and set a "neutral" rating on the stock in a report on Tuesday, March 4th. Finally, Leerink Partners lowered Hologic from an "outperform" rating to a "market perform" rating and reduced their target price for the stock from $80.00 to $75.00 in a report on Thursday, February 6th. Eleven equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $84.62.

Hologic Trading Up 0.5 %

NASDAQ:HOLX traded up $0.30 during mid-day trading on Wednesday, hitting $58.49. 414,625 shares of the company's stock were exchanged, compared to its average volume of 1,949,464. Hologic, Inc. has a fifty-two week low of $55.89 and a fifty-two week high of $84.67. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52. The firm has a market capitalization of $13.12 billion, a P/E ratio of 18.45, a PEG ratio of 2.14 and a beta of 0.82. The company has a 50 day simple moving average of $61.34 and a 200-day simple moving average of $70.45.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, topping analysts' consensus estimates of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. As a group, research analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.